Biogennix company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biogennix.com

About Biogennix

Biogennix develops products for bone fusion. The company's osteoSPAN fusion kit is utilized in transverse process fusion.

Biogennix Headquarter Location

18011 Sky Park Circle Suite M

Irvine, California, 92614,

United States

949-253-0994

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biogennix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biogennix is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Latest Biogennix News

Biogennix Reports Record Year for Sales in 2021

Jan 25, 2022

01/25/2022 | 01:48pm EST Message : *Required fields Irvine-based Biogennix , an advanced osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that 2021 was the best sales year in company history. The company also announced that the third and fourth quarters of 2021 were the best performing six months for the company to date. “Despite challenges faced by the industry over the past two years due to the global pandemic, Biogennix has been able to maintain our momentum throughout 2021, and thanks to a particularly strong second half of 2021, we were able to exceed expectations,” said Chris MacDuff, Biogennix’s CEO. “Our continued growth last year was also fueled by the launch of our first advanced bone graft strip product, Agilon® Strip, which expands our TrelCor-based Agilon product family.” MacDuff mentioned that Biogennix also saw increasing sales for its newest moldable bone graft product, Agilon Moldable , particularly in the foot & ankle surgery market, due to its advanced TrelCor material properties and best-in-class handling. The company also continued to see consistently strong growth of Agilon Moldable in the spine market segment. “It was rewarding to celebrate the tenth anniversary of our first clinical case last year while also experiencing our strongest growth year yet,” added MacDuff. “We look forward to further growth in 2022, with several new product launches and exciting initiatives being introduced throughout the year.” Biogennix’s proprietary TrelCor technology is a bioactive synthetic material engineered to jumpstart patients’ natural healing processes. TrelCor technology uniquely combines multiple cutting-edge scientific principles into one advanced material that actively promotes cellular healing and new bone formation. Biogennix proprietary bone graft technologies have been implanted over 50,000 times since the initial market release in 2011. Biogennix designs, manufactures and distributes all of its products from its Irvine facilities. Biogennix® is a fully-integrated advanced osteobiologics company headquartered in Irvine which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures. Biogennix is committed to advancing technology behind next-generation bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence. Learn more at biogennix.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20220125006033/en/ © Business Wire 2022

Biogennix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biogennix Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.